Cystic FibrosisProspectiveNCT04395820
Prospective Surveillance of Lung Development During Childhood, Adolescence and Adulthood in Healthy and Patients With Cystic Fibrosis
An observational study of Cystic Fibrosis and Healthy, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.
Trial summary
Cystic fibrosis (CF) is the most common lethal inherited disease in Caucasian populations. To improve survival, it is essential to understand the development, progression and treatment of CF lung disease throughout early childhood. Read more about this study
- Who is it for?
- Ages 3 to 18 yearsHealthy volunteers can take part
- Conditions the study is for
- Cystic Fibrosis, Healthy
- What is being tested?
- Lung function test and Imaging
- How many people
- 250 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Jul 2020to 1 Dec 2100
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 to 18 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Study population: Children and adults with CF and healthy volunteers from the local community in Bern and surrounding areas.
Who may be able to join
- Individuals with CF:
- Diagnosis of CF
- Signed written informed consent
- ≥3 - 18 years of age, depending on the cooperation and if lung function measurements are possible
- Healthy volunteers:
- Signed written informed consent
Show all 9Show fewer
- Informed consent of participant and if under 18 years, legal representative respectively
- Children and adults with no history of chronic lung disease or acute respiratory infection in the four weeks prior to the study visit
- ≥3 - 18 years of age, depending on the cooperation and if lung function measurements are possible
Who cannot join
- The presence of any one of the following exclusion criteria will lead to exclusion of the participant, for example:
- Women who are pregnant or breast feeding.
- Intention to become pregnant during the course of the study
- Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases.
- Please note that female participants who are surgically sterilised/hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential.
- Other clinically significant concomitant disease states (e.g. renal failure, hepatic dysfunction, cardiovascular disease, etc.)
Show all 19Show fewer
- Known or suspected non-compliance, drug or alcohol abuse
- Continuous glucose monitor
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, etc. of the participant
- Metal in body, e.g. pacemaker
- Participation in another study with investigational drug within the 30 days preceding and during the present study
- Subjects which are respiratory insufficient to attend on the lung function measurements (oxygen demand)
- Subjects who are unable to perform the MRI without sedation
- Participants which were born preterm (<36. week of pregnancy)
- Current smokers
- In addition for individuals with CF:
- Known diseases other than related to CF
- In addition for healthy individuals:
- Current upper respiratory infection (cough, cold, fever) will lead to postponement of the visit to 4 weeks after the end of symptoms
Trial locations and contacts
1 site in 1 country.
About this study
Cystic fibrosis (CF) is the most common lethal inherited disease in Caucasian populations. To improve survival, it is essential to understand the development, progression and treatment of CF lung disease throughout early childhood.
Therefore the overall objective is to prospectively assess the clinical utility of novel and non-invasive measuring methods, namely Multiple Breath Washout and functional lung MRI in the longitudinal clinical surveillance of patients with CF and compare the results to those of healthy controls.
Read the detailed description
Background and project rationale:
Cystic fibrosis (CF), the most common lethal inherited disease in Caucasian populations, affects approximately 1:2500 live births. It is a multisystem disorder with respiratory morbidity and mortality being the leading cause of death. Despite improved survival in successive birth cohorts, the current median survival age of patients with CF is about 40 years. To improve survival, it is essential to understand the development, progression and treatment of CF lung disease throughout early childhood. Therefore tracking of lung function throughout childhood may provide important insights into the development and progression of CF lung disease. Spirometry, the standard lung function test for decades, is sensitive only for airflow limitation arising in large airways and insensitive for assessment of small or peripheral airway involvement, whereby the CF lung disease emerges in the small airways. Two promising techniques to assess small airway function in young children include the multiple breath washout (MBW) lung function test and functional Matrix-Pencil magnetic resonance imaging (MP-MRI).
Project Objectives and Design:
The overall objective of this project is to prospectively assess the clinical utility of MBW and MP-MRI in the longitudinal clinical surveillance of patients with CF. Therefore this study: i) Examines differences in MBW and MP-MRI outcomes between patients with CF and healthy controls. ii) Assesses the short term (over 1h) repeatability of MBW and MP-MRI outcomes in patients with CF and healthy controls. iii) Assesses whether MBW and MP-MRI outcomes are associated with clinical lung disease in patients with CF. iv) Determines whether changes in MBW and MP-MRI outcomes are associated with progression of lung disease in patients with CF. v) Compares the breath-by-breath regional and temporal changes in functional MRI signal with breath-by-breath changes in MBW phase outcomes in patients with CF and healthy controls.
Methods:
Data of MBW, MP-MRI, morphological MRI, Spirometry and body plethysmography, clinical respiratory symptoms and microbiology will be collected during this study.
Recruitment and participation:
Children and adults with CF will be recruited from the outpatient and inpatient clinics at the Inselspital in Bern. Healthy controls will be recruited from the local community in Bern and surrounding areas.
Information collected:
Lung function:
- Multiple Breath Washout (FRC, LCI, Scond, Sacin)
- Spirometry (FEV1, FVC, FEFx)
- Body plethysmography (sReff, FRCpletz, TLC)
Respiratory symptoms and clinical data:
CF:
- respiratory symptoms (cough, sputum characteristics, shortness of breath, weight loss, appetite fatigue)
- clinical data (increased work of breathing, hypoxemia, wheeze, crackles, differential air entry)
Healthy controls:
Presence of respiratory symptoms in the last four weeks preceding visit.
Functional and structural MRI:
- Functional MRI (percentage of the lung volume with impaired fractional ventilation (RFV) and relative perfusion (RQ)
- Structural MRI( Eichinger MRI scoring system to assess the presence and extent of bronchiectasis, mucous plugging, and air trapping)
Medical history:
CF: demographics, genetic mutation, pulmonary exacerbations, hospitalisations, regular therapy and medication, complications, microbiological data and laboratory reports
Microbiology:
CF: bacterial analysis of oropharyngeal swabs
Quality of life:
CF: CF-specific quality of life and symptoms
Sputum:
CF:
- spontaneously expectorated sputum
- Induced sputum
Study database:
All study data is recorded in an Access-database with SQL Servers. The database is accordant to the HFG and was adapted together with the CTU.
Funding:
The Swiss National Foundation (32003B_182719) and Vertex-Pharmaceuticals Cystic Fibrosis Research Innovation Award provide financial and material support for this observational study
- Conditions
- Cystic Fibrosis, Healthy
- Being tested
- Lung function test, Imaging
- Keywords
- Cystic Fibrosis, MBW, MRI, Airway growth, Airway development, Healthy
- Medical subject headings
- Cystic Fibrosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lung function testDiagnostic test
MBW
ImagingDiagnostic test
MP-MRI
| Study group | Role | What they receive |
|---|---|---|
| Cystic Fibrosis | Not described Receives: Diagnostic Test: Lung function test; Diagnostic Test: Imaging | |
| Healthy | Not described Receives: Diagnostic Test: Lung function test; Diagnostic Test: Imaging |
What is being measured
The primary outcome is the main question the study is designed to answer.
Multiple Breath Washout
Longitudinal assessment of lung volume and ventilation inhomogeneity
Measured: Every third month up to 50 years. Healthy controls only during 1 year.
Functional MP-MRI
Longitudinal assessment of percentage of the lung volume with impaired fractional ventilation and relative perfusion
Measured: Every twelfth month up to 50 years. Healthy controls only during 1 year (2 time points).
Secondary outcomes (12)
Morphological MRI
Longitudinal assessment of the presence and extent of bronchiectasis, mucous plugging and air trapping by Eichinger MRI scoring.
Measured: Every twelfth month up to 50 years. Healthy controls only during 1 year (2 time points)
Spirometry: FEV1
Longitudinal assessment of forced expired volume in 1 second.
Measured: Every third month up to 50 years. Healthy controls only during 1 year.
Spirometry: FVC
Longitudinal assessment of forced vital capacity.
Measured: Every third month up to 50 years. Healthy controls only during 1 year.
Spirometry: FEF
Longitudinal assessment of forced expiratory flows.
Measured: Every third month up to 50 years. Healthy controls only during 1 year.
Body plethysmography: sRAW
Longitudinal assessment of specific airway resistance.
Measured: Every third month up to 50 years. Healthy controls only during 1 year.
Body plethysmography: FRC
Longitudinal assessment of functional residual capacity.
Measured: Every third month up to 50 years. Healthy controls only during 1 year.
Body plethysmography: TLC
Longitudinal assessment of total lung capacity.
Measured: Every third month up to 50 years. Healthy controls only during 1 year.
Respiratory symptoms
Longitudinal assessment of clinical respiratory symptoms.
Measured: Every third month up to 50 years. Only CF patients.
Exacerbations
Longitudinal assessment of clinical status.
Measured: Every third month up to 50 years. Only CF patients.
CF-related quality of life
Longitudinal assessment of standardised age-specific CF-related quality of life questions.The scale goes from 0-100, higher score means better outcome.
Measured: Every third month up to 50 years. Only CF patients.
Microbiology: presence of respiratory pathogens
Longitudinal assessment of presence of respiratory pathogens from oropharyngeal swabs and sputum samples.
Measured: Every third month up to 50 years. Only CF patients.
Microbiology: abundance of respiratory pathogens
Longitudinal assessment of abundance of respiratory pathogens from oropharyngeal swabs and sputum samples.
Measured: Every third month up to 50 years. Only CF patients.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 May 2020
- Study start1 Jul 2020
- Primary completion1 Dec 2050 (estimated)
- Study completion1 Dec 2100 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Cystic FibrosisStudies of the same condition, open and under way.
- More trials run by Insel Gruppe AG, University Hospital BernThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 250 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kathryn Ramsey, Insel Gruppe AG, University Hospital Bern
- Investigators
- Kathryn Ramsey, PhD, Principal investigator, University Children's Hospital Bern
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04395820
- Sponsor's protocol ID
- 2019-01591
- Other IDs
- 2019
- Acronym
- Prospective
- Status last verified
- Nov 2020
- First submitted
- 5 May 2020
- Last updated
- 4 Nov 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009 May 30;373(9678):1891-904. doi: 10.1016/S0140-6736(09)60327-5. Epub 2009 May 4.
PubMed 19403164Ramsey KA, Ranganathan S, Park J, Skoric B, Adams AM, Simpson SJ, Robins-Browne RM, Franklin PJ, de Klerk NH, Sly PD, Stick SM, Hall GL; AREST CF. Early respiratory infection is associated with reduced spirometry in children with cystic fibrosis. Am J Respir Crit Care Med. 2014 Nov 15;190(10):1111-6. doi: 10.1164/rccm.201407-1277OC.
PubMed 25321321
Study at a glance
From the registry record, last updated by the sponsor on 4 Nov 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Surveillance of Lung Development During Childhood, Adolescence and Adulthood in Healthy and Patients With Cystic Fibrosis
- ClinicalTrials.gov ID
- NCT04395820
- Acronym / sponsor ID
- Prospective / 2019-01591
- Conditions
- Cystic Fibrosis, Healthy
- Keywords
- Cystic Fibrosis, MBW, MRI, Airway growth, Airway development, Healthy
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 250 participants (estimated)
- Lead sponsor
- Insel Gruppe AG, University Hospital BernUniversity, hospital or other
- Study start
- 1 Jul 2020 (actual)
- Primary completion
- 1 Dec 2050 (estimated)
- Study completion
- 1 Dec 2100 (estimated)
- First posted
- 20 May 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cystic fibrosis (CF) is the most common lethal inherited disease in Caucasian populations. To improve survival, it is essential to understand the development, progression and treatment of CF lung disease throughout early childhood.
Therefore the overall objective is to prospectively assess the clinical utility of novel and non-invasive measuring methods, namely Multiple Breath Washout and functional lung MRI in the longitudinal clinical surveillance of patients with CF and compare the results to those of healthy controls.
Detailed description
Background and project rationale:
Cystic fibrosis (CF), the most common lethal inherited disease in Caucasian populations, affects approximately 1:2500 live births. It is a multisystem disorder with respiratory morbidity and mortality being the leading cause of death. Despite improved survival in successive birth cohorts, the current median survival age of patients with CF is about 40 years. To improve survival, it is essential to understand the development, progression and treatment of CF lung disease throughout early childhood. Therefore tracking of lung function throughout childhood may provide important insights into the development and progression of CF lung disease. Spirometry, the standard lung function test for decades, is sensitive only for airflow limitation arising in large airways and insensitive for assessment of small or peripheral airway involvement, whereby the CF lung disease emerges in the small airways. Two promising techniques to assess small airway function in young children include the multiple breath washout (MBW) lung function test and functional Matrix-Pencil magnetic resonance imaging (MP-MRI).
Project Objectives and Design:
The overall objective of this project is to prospectively assess the clinical utility of MBW and MP-MRI in the longitudinal clinical surveillance of patients with CF. Therefore this study: i) Examines differences in MBW and MP-MRI outcomes between patients with CF and healthy controls. ii) Assesses the short term (over 1h) repeatability of MBW and MP-MRI outcomes in patients with CF and healthy controls. iii) Assesses whether MBW and MP-MRI outcomes are associated with clinical lung disease in patients with CF. iv) Determines whether changes in MBW and MP-MRI outcomes are associated with progression of lung disease in patients with CF. v) Compares the breath-by-breath regional and temporal changes in functional MRI signal with breath-by-breath changes in MBW phase outcomes in patients with CF and healthy controls.
Methods:
Data of MBW, MP-MRI, morphological MRI, Spirometry and body plethysmography, clinical respiratory symptoms and microbiology will be collected during this study.
Recruitment and participation:
Children and adults with CF will be recruited from the outpatient and inpatient clinics at the Inselspital in Bern. Healthy controls will be recruited from the local community in Bern and surrounding areas.
Information collected:
Lung function:
- Multiple Breath Washout (FRC, LCI, Scond, Sacin)
- Spirometry (FEV1, FVC, FEFx)
- Body plethysmography (sReff, FRCpletz, TLC)
Respiratory symptoms and clinical data:
CF:
- respiratory symptoms (cough, sputum characteristics, shortness of breath, weight loss, appetite fatigue)
- clinical data (increased work of breathing, hypoxemia, wheeze, crackles, differential air entry)
Healthy controls:
Presence of respiratory symptoms in the last four weeks preceding visit.
Functional and structural MRI:
- Functional MRI (percentage of the lung volume with impaired fractional ventilation (RFV) and relative perfusion (RQ)
- Structural MRI( Eichinger MRI scoring system to assess the presence and extent of bronchiectasis, mucous plugging, and air trapping)
Medical history:
CF: demographics, genetic mutation, pulmonary exacerbations, hospitalisations, regular therapy and medication, complications, microbiological data and laboratory reports
Microbiology:
CF: bacterial analysis of oropharyngeal swabs
Quality of life:
CF: CF-specific quality of life and symptoms
Sputum:
CF:
- spontaneously expectorated sputum
- Induced sputum
Study database:
All study data is recorded in an Access-database with SQL Servers. The database is accordant to the HFG and was adapted together with the CTU.
Funding:
The Swiss National Foundation (32003B_182719) and Vertex-Pharmaceuticals Cystic Fibrosis Research Innovation Award provide financial and material support for this observational study
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cystic Fibrosis | – | Diagnostic Test: Lung function test, Diagnostic Test: Imaging |
| Healthy | – | Diagnostic Test: Lung function test, Diagnostic Test: Imaging |
Who may qualify
- Ages
- 3 to 18 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
- Study population
- Children and adults with CF and healthy volunteers from the local community in Bern and surrounding areas.
Key inclusion criteria (9 listed)
- Diagnosis of CF
- Signed written informed consent
- ≥3 - 18 years of age, depending on the cooperation and if lung function measurements are possible
- Signed written informed consent
- Informed consent of participant and if under 18 years, legal representative respectively
Key exclusion criteria (19 listed)
- The presence of any one of the following exclusion criteria will lead to exclusion of the participant, for example:
- Women who are pregnant or breast feeding.
- Intention to become pregnant during the course of the study
- Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases.
- Please note that female participants who are surgically sterilised/hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lung function testMBW | Diagnostic test | Cystic Fibrosis, Healthy |
| ImagingMP-MRI | Diagnostic test | Cystic Fibrosis, Healthy |
Primary outcome
Multiple Breath Washout
Time frame: Every third month up to 50 years. Healthy controls only during 1 year.
Longitudinal assessment of lung volume and ventilation inhomogeneity
Functional MP-MRI
Time frame: Every twelfth month up to 50 years. Healthy controls only during 1 year (2 time points).
Longitudinal assessment of percentage of the lung volume with impaired fractional ventilation and relative perfusion
12 secondary outcomes
Morphological MRI
Time frame: Every twelfth month up to 50 years. Healthy controls only during 1 year (2 time points)
Spirometry: FEV1
Time frame: Every third month up to 50 years. Healthy controls only during 1 year.
Spirometry: FVC
Time frame: Every third month up to 50 years. Healthy controls only during 1 year.
Spirometry: FEF
Time frame: Every third month up to 50 years. Healthy controls only during 1 year.
Body plethysmography: sRAW
Time frame: Every third month up to 50 years. Healthy controls only during 1 year.
Body plethysmography: FRC
Time frame: Every third month up to 50 years. Healthy controls only during 1 year.
Body plethysmography: TLC
Time frame: Every third month up to 50 years. Healthy controls only during 1 year.
Respiratory symptoms
Time frame: Every third month up to 50 years. Only CF patients.
Exacerbations
Time frame: Every third month up to 50 years. Only CF patients.
CF-related quality of life
Time frame: Every third month up to 50 years. Only CF patients.
Microbiology: presence of respiratory pathogens
Time frame: Every third month up to 50 years. Only CF patients.
Microbiology: abundance of respiratory pathogens
Time frame: Every third month up to 50 years. Only CF patients.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Nov 2020.
- Background: PubMed 19403164O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009 May 30;373(9678):1891-904. doi: 10.1016/S0140-6736(09)60327-5. Epub 2009 May 4.
- Background: PubMed 25321321Ramsey KA, Ranganathan S, Park J, Skoric B, Adams AM, Simpson SJ, Robins-Browne RM, Franklin PJ, de Klerk NH, Sly PD, Stick SM, Hall GL; AREST CF. Early respiratory infection is associated with reduced spirometry in children with cystic fibrosis. Am J Respir Crit Care Med. 2014 Nov 15;190(10):1111-6. doi: 10.1164/rccm.201407-1277OC.
Related trials for Cystic Fibrosis
RecruitingPhase 2
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis
Non-cystic Fibrosis Bronchiectasis
Active, not recruitingObservational study
CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis
Cystic Fibrosis, Bone Loss
RecruitingObservational study
Natural History of Bronchiectasis
Bronchiectasis, Cystic Fibrosis
RecruitingObservational study
Role of Genetic Factors in the Development of Lung Disease
Cystic Fibrosis, Pulmonary Fibrosis
RecruitingPhase 2
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.
Cystic Fibrosis - Complete
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kathryn Ramsey, PhD principal investigator
University Children's Hospital Bern
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cystic Fibrosis and Healthy, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 4 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Multiple Breath Washout (time frame: Every third month up to 50 years. Healthy controls only during 1 year.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04395820, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2020.